Royalty Pharma PLC Class A RPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPRX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBP 498.00
- Day Range
- GBP 482.00–482.00
- 52-Week Range
- GBP 463.34–531.50
- Bid/Ask
- GBP 482.00 / GBP 482.00
- Market Cap
- GBP 215.31 Bil
- Volume/Avg
- 20,600 / 6,339
Key Statistics
- Price/Earnings (Normalized)
- 35.74
- Price/Sales
- 7.46
- Dividend Yield (Trailing)
- 2.86%
- Dividend Yield (Forward)
- 48.99%
- Total Yield
- 5.40%
Company Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 89
- Website
- https://www.royaltypharma.com
Competitors
Valuation
Metric
|
RPRX
|
VRTX
|
PFE
|
---|---|---|---|
Price/Earnings (Normalized) | 35.74 | 24.97 | 19.85 |
Price/Book Value | 2.01 | 5.89 | 1.75 |
Price/Sales | 7.46 | 10.82 | 2.92 |
Price/Cash Flow | 6.42 | 26.12 | 18.72 |
Price/Earnings
RPRX
VRTX
PFE
Financial Strength
Metric
|
RPRX
|
VRTX
|
PFE
|
---|---|---|---|
Quick Ratio | 7.87 | 3.15 | 0.58 |
Current Ratio | 7.90 | 3.50 | 0.91 |
Interest Coverage | 9.70 | 95.99 | 0.74 |
Quick Ratio
RPRX
VRTX
PFE
Profitability
Metric
|
RPRX
|
VRTX
|
PFE
|
---|---|---|---|
Return on Assets (Normalized) | −7.77% | 20.50% | 4.98% |
Return on Equity (Normalized) | −20.42% | 26.75% | 10.90% |
Return on Invested Capital (Normalized) | −7.10% | 22.49% | 7.28% |
Return on Assets
RPRX
VRTX
PFE
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mfmtglrh | Hgsyb | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lksxgzqjk | Mxlhnl | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xbljhymt | Qwjdly | $107.6 Bil | |
MRNA
| Moderna Inc | Bgkddnhv | Ngr | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Khkrrqyrg | Kmw | $22.3 Bil | |
ARGX
| argenx SE ADR | Wdplftmq | Ccnz | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hsjtjyby | Wxwnrf | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mfljfbtp | Jlnyw | $15.3 Bil | |
INCY
| Incyte Corp | Vncgwqpfd | Xggqbpq | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jpwgypwrss | Prmlxhs | $12.7 Bil |